Bailey.Glen at 18:42, 3 November 2023

2023-11-03T18:42:49Z

@@ Line 1: / Line 1: @@
 {{Under Construction}}
 ==Primary Author(s)*==
@@ Line 188: / Line 193: @@
 ==Notes==
 <nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.

Bailey.Glen: Created page with "{{Under Construction}} ==Primary Author(s)*== '''Sarah Rapisardo, PhD, FACMG''' | Assistant Professor, Pathology Associate Director | Division of Molecular Pathology, Geneti..."

2023-11-03T18:01:17Z

Created page with "{{Under Construction}} ==Primary Author(s)*== '''Sarah Rapisardo, PhD, FACMG''' | Assistant Professor, Pathology Associate Director | Division of Molecular Pathology, Geneti..."

New page

{{Under Construction}}
==Primary Author(s)*==

'''Sarah Rapisardo, PhD, FACMG''' | Assistant Professor, Pathology

Associate Director | Division of Molecular Pathology, Genetics and Genomics

Duke University Health System Clinical Laboratories

__TOC__

==Cancer Category/Type==

Myeloproliferative neoplasm

==Cancer Sub-Classification / Subtype==

Juvenile myelomonocytic leukemia (JMML)

==Definition / Description of Disease==

JMML is a clonal hematopoietic disorder of childhood characterized by proliferation of the granulocytic and monocytic lineages.

==Synonyms / Terminology==

Juvenile chronic myelomonocytic leukemia

==Epidemiology / Prevalence==

JMML is a rare disease, with an annual incidence of approximately 0.13 cases per 100,000 children 0-14 years of age (WHO: Baumann I et al). Patient age at diagnosis ranges from 1 month to early adolescence, with a median age at presentation of 2 years (WHO: Baumann I et al, Caywood and Kolb, UpToDate). There is a male predominance, with boys affected nearly twice as frequently as girls.

==Clinical Features==

Children with JMML typically present with symptoms related to infiltration of the bone marrow and other organs. Approximately one half of all patients have lymphadenopathy (WHO), and one-third of children will have an acute presentation with fever, signs of upper respiratory infection, organomegaly, and cutaneous findings (Caywood and Kolb, UpToDate).

==Sites of Involvement==

Peripheral blood and bone marrow. In nearly all cases, leukemic infiltration of the liver and spleen is found; any tissue can be infiltrated, most commonly the lymph nodes, skin, respiratory system and gut. (WHO: Baumann I et al).

==Morphologic Features==

A peripheral blood smear is the most important specimen for diagnosis and typically shows leukocytosis, thrombocytopenia, and anemia (WHO: Baumann I et al). Bone marrow findings typically include hypercellularity with granulocytic proliferation, with <20% blasts and minimal dysplasia (WHO: Baumann I et al).

==Immunophenotype==

Put your text here and/or fill in the table

{| class="wikitable sortable"
|-
!Finding!!Marker
|-
|Positive (universal)||EXAMPLE CD1
|-
|Positive (subset)||EXAMPLE CD2
|-
|Negative (universal)||EXAMPLE CD3
|-
|Negative (subset)||EXAMPLE CD4
|}

==Chromosomal Rearrangements (Gene Fusions)==

Chromosomal translocations resulting in fusion genes have been only rarely reported in JMML patients with monosomy 7 (without mutations in the canonical RAS pathway)<ref>{{Cite journal|last=Meynier|first=Sonia|last2=Rieux-Laucat|first2=Frédéric|date=2020-09|title=After 95 years, it's time to eRASe JMML|url=https://pubmed.ncbi.nlm.nih.gov/31980238|journal=Blood Reviews|volume=43|pages=100652|doi=10.1016/j.blre.2020.100652|issn=1532-1681|pmid=31980238}}</ref>.

Importantly, exclusion of ''KMT2A'' rearrangements and the absence of ''BCR::ABL1'' are diagnostic criteria for JMML. (PMID: Arber ICC PMID: 35767897 and Khoury WHO PMID: 35732831)

 
==Characteristic Chromosomal Aberrations / Patterns==
{| class="wikitable"
|'''Prevalence'''
|'''Karyotype'''
|-
|25%
|Monosomy 7
|-
|10%
|Other abnormalities
|-
|65%
|Normal karyotype
|}
 
==Genomic Gain/Loss/LOH==

Put your text here and/or fill in the table

{| class="wikitable sortable"
|-
!Chromosome Number!!Gain/Loss/Amp/LOH!!Region
|-
|EXAMPLE 8||EXAMPLE Gain||EXAMPLE chr8:0-1000000
|-
|EXAMPLE 7||EXAMPLE Loss||EXAMPLE chr7:0-1000000
|}

==Gene Mutations (SNV/INDEL)==

Frequent gene mutations<ref>{{Cite journal|last=Niemeyer|first=Charlotte M.|date=2018-11-30|title=JMML genomics and decisions|url=https://pubmed.ncbi.nlm.nih.gov/30504325|journal=Hematology. American Society of Hematology. Education Program|volume=2018|issue=1|pages=307–312|doi=10.1182/asheducation-2018.1.307|issn=1520-4383|pmc=6245977|pmid=30504325}}</ref> are summarized below:

{| class="wikitable sortable"
|-
!Gene!!Mutation!!Oncogene/Tumor Suppressor/Other!!Presumed Mechanism (LOF/GOF/Other; Driver/Passenger)!!Prevalence (COSMIC/TCGA/Other)
|-
|''PTPN11''
|Multiple
|Oncogene
|Somatic GOF
|40%
|-
|''KRAS, NRAS''
|G12, G13, Q61
|Oncogene
|Somatic GOF
|15-20%
|-
|''NF1''
|Multiple
|Tumor Suppressor
|Germline mutation with acquired biallelic inactivation in hematopoietic cells
|10-15%
|-
|''CBL''
|Multiple
|Tumor Suppressor
|Germline mutation with acquired biallelic inactivation in hematopoietic cells
|10-15%
|}

===Other Mutations===
Secondary molecular abnormalities have been reported in JMML.
{| class="wikitable sortable"
|-
!Type!!Gene/Region/Other
|-
|Other Mutated Genes Identified by Exome Sequencing||''ASXL1, DNMT3A, EZH2, GATA2, RRAS, RRAS2, RUNX1, SETBP1, SH2B3, ZRSR2 (''Stieglitz E et al, <nowiki>PMID 26457647</nowiki>)
|-
|Mutually Exclusive||Although driver mutations in ''NRAS'', ''KRAS'', ''PTPN11'', ''CBL1'', and ''NF1'' typically thought to be mutually exclusive, coexisting mutations were identified in 11% of patients (Stieglitz E et al, <nowiki>PMID 26457647</nowiki>).
|}

==Epigenomics (Methylation)==

Mutations in epigenetic modifiers genes including ''ASXL1'', ''EZH2'', and ''DNMT3A'' are observed in a subset of JMML (identified 14% of patients).<ref>{{Cite journal|last=Stieglitz|first=Elliot|last2=Taylor-Weiner|first2=Amaro N.|last3=Chang|first3=Tiffany Y.|last4=Gelston|first4=Laura C.|last5=Wang|first5=Yong-Dong|last6=Mazor|first6=Tali|last7=Esquivel|first7=Emilio|last8=Yu|first8=Ariel|last9=Seepo|first9=Sara|date=2015-11|title=The genomic landscape of juvenile myelomonocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/26457647|journal=Nature Genetics|volume=47|issue=11|pages=1326–1333|doi=10.1038/ng.3400|issn=1546-1718|pmc=4626387|pmid=26457647}}</ref>

==Genes and Main Pathways Involved==

Molecular driver mutations within the RAS signaling pathway genes ''PTPN11'', ''NRAS'', ''KRAS'', ''NF1'', and ''CBL'' are identified in 85-90% of patients with JMML.

==Diagnostic Testing Method<ref>{{Cite journal|last=Arber|first=Daniel A.|last2=Orazi|first2=Attilio|last3=Hasserjian|first3=Robert P.|last4=Borowitz|first4=Michael J.|last5=Calvo|first5=Katherine R.|last6=Kvasnicka|first6=Hans-Michael|last7=Wang|first7=Sa A.|last8=Bagg|first8=Adam|last9=Barbui|first9=Tiziano|date=2022-09-15|title=International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data|url=https://pubmed.ncbi.nlm.nih.gov/35767897|journal=Blood|volume=140|issue=11|pages=1200–1228|doi=10.1182/blood.2022015850|issn=1528-0020|pmc=9479031|pmid=35767897}}</ref>==

*Clinical and hematologic features:
**Peripheral blood monocyte count > 1 x 109/L (present in most cases)
**Splenomegaly (present in >95 % cases at presentation)
**Blast percentage in peripheral blood and bone marrow < 20%
**Absence of ''BCR::ABL1''
*Genetic studies (one finding required):
**Somatic mutation in ''PTPN11, KRAS, NRAS,'' or ''RRAS''
**Germline ''NF1'' mutation and loss of heterozygosity of ''NF1'' or clinical diagnosis of neurofibromatosis type 1
**Germline ''CBL'' mutation and loss of heterozygosity of ''CBL''

==Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications)==

The progression of JMML is variable. While some studies identify a prognostic difference based on the molecular driver mutation, with ''PTPN11, KRAS,'' and ''NRAS'' mutations showing a more aggressive disease course (WHO: Baumann I et al), another report identified the number of mutations present at diagnosis (rather than the type of mutations), as a prognostic factor, with patients harboring two or more somatic alterations at diagnosis having worst event-free and overall survival rates than those with one or no mutations (Stieglitz E et al, <nowiki>PMID 26457647</nowiki>). Spontaneous regression of JMML is observed in most children with ''CBL'' mutations. The only curative treatment is allogeneic stem cell transplant, with a 5-year event free survival of approximately 44-53% (Meynier S and Rieux-Laucat, <nowiki>PMID 31980238</nowiki>).

==Genetic Susceptibility==

Approximately 25% of patients with JMML have inherited syndromes that predispose to the development of JMML (Stieglitz E et al, <nowiki>PMID 26457647</nowiki>). Specifically, the RASopathies are a class of autosomal dominant developmental disorders caused by germline mutations in the Ras/MAPK signaling pathway, with clinical features that include facial dysmorphism; cardiac defects; cutaneous, musculoskeletal, and ocular abnormalities; reduced growth; neurocognitive deficits; and increase cancer risk (including JMML) (Rauen KA, <nowiki>PMID 23875798</nowiki>). Increased risk of JMML is reported in the following RASopathies:

1. Neurofibromatosis type I (OMIM '''#''' 162200) with germline mutations in the ''NF1'' gene.

2. Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia (OMIM #613563) with germline mutations in the ''CBL'' gene.

3. Noonan syndrome (OMIM # 163950) with germline mutations in ''PTPN11''.
==Other Information==

Put your text here

==Links==

Put your links here (use "Link" icon at top of page)

==References==
<references />(use "Cite" icon at top of page)

===EXAMPLE Book===

#Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.

==Notes==
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.

HAEM4:Juvenile Myelomonocytic Leukemia (JMML) - Revision history

Bailey.Glen at 18:42, 3 November 2023

Bailey.Glen: Created page with "{{Under Construction}} ==Primary Author(s)*== '''Sarah Rapisardo, PhD, FACMG''' | Assistant Professor, Pathology Associate Director | Division of Molecular Pathology, Geneti..."